On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Companyﾒs COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community.

The terms provides for the delivery of NVX-CoV2373 to Australia starting as early as the first half of 2021, subject to the successful completion of Phase 3 clinical development and approval of the vaccine by Australiaﾒs Therapeutic Goods Administration.